Sangeetha Venugopal, MD

Articles by Sangeetha Venugopal, MD

Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Listen Now
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | July 2, 2024
The expert panel discusses current issues in the use of ESAs within MDS management.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | July 1, 2024
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 21, 2024
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | August 29, 2024
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 17, 2024
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 13, 2024
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
Sangeetha Venugopal, MDChronic Myeloid Leukemia | June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Elias Jabbour, MDThe HemOnc Pulse Live | May 21, 2024
The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | May 13, 2024
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | January 12, 2024
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | January 4, 2024
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel addresses continued MDS research needs.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel shares their thoughts on the full analysis of the COMMANDS study.
Guillermo Garcia-Manero, MDVideo Insights | January 4, 2024
The panel discussed the current slate of treatment options for patients with low-risk MDS.
Sangeetha Venugopal, MDMyelofibrosis | March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.